Abstract
Systemic therapy has historically been the backbone of treatment for patients with metastatic disease. However, recent evidence suggests metastasis-directed therapy in those with oligometastatic disease (≤5 lesions) may improve progression-free and overall survival. Within prostate cancer-specific cohorts, metastasis-directed therapy also appears to delay the time to initiation of androgen deprivation therapy while also generally being associated with a mild toxicity profile and has thus garnered interest as a means to delay systemic therapy. Here we review the evidence surrounding the use of radiation therapy to metastatic sites in patients with metastatic hormone-sensitive prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 87-93 |
Number of pages | 7 |
Journal | Cancer Journal (United States) |
Volume | 26 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2020 |
Keywords
- Hormone sensitive
- metastasis directed therapy
- oligometastatic
- prostate cancer
- stereotactive ablative radiation therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research